Tradipitant is a Small Molecule owned by Vanda Pharmaceuticals, and is involved in 16 clinical trials, of which 12 were completed, 3 are ongoing, and 1 is planned.
Tradipitant (VLY-686, LY-686017) is a neurokinin-1 (NK-1) receptor, antagonist. Neurokinin 1 receptor (NK1R) is a mediator of behavioural stress responses, in alcohol dependence and treatment. NK1R deficiency decreases voluntary alcohol consumption and increases sensitivity to the sedative effects of alcohol. In the skin, tissue-resident cells such as keratinocytes, mast cells and cells of the inflammatory infiltrate including lymphocytes and eosinophils interact with neuronal cells. The drug candidate by antagonizing NK-1R reduces over-stimulation of the NK-1R and ameliorates the condition.
The revenue for Tradipitant is expected to reach a total of $328m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Tradipitant NPV Report.
Tradipitant was originated by Eli Lilly and Co and is currently owned by Vanda Pharmaceuticals.
Tradipitant (VLY-686, LY-686017) is under development for the treatment of gastroparesis, functional dyspepsia and motion sickness. It is administered through oral route as a capsule. The drug candidate is a new chemical entity that targets neurokinin-1 (NK-1) receptor. LY-686017 was also under development for the treatment of anxiety, social phobia, craving during anxiety associated alcohol dependence and treatment-resistant pruritus in atopic dermatitis.
It was under development for the treatment of pneumonia associated with Coronavirus disease 2019 (COVID-19).
Vanda Pharmaceuticals Overview
Vanda Pharmaceuticals (Vanda) a biopharmaceutical company that develops and commercializes novel therapies for the treatment of central nervous system disorders. The company’s products include Hetlioz, a melatonin receptor agonist for the treatment of non-24-hour sleep-wake disorder; and Fanapt, a typical antipsychotic for the treatment of schizophrenia in adults. Its major pipeline products include Tradipitant (VLY-686), VTR-297, VQW-765, CFTR and portfolio of cystic fibrosis transmembrane conductance regulator inhibitors and activators. Vanda is headquartered in Washington, Washington DC, the US.
The company reported revenues of (US Dollars) US$268.7 million for the fiscal year ended December 2021 (FY2021), an increase of 8.3% over FY2020. In FY2021, the company’s operating margin was 15.7%, compared to an operating margin of 11% in FY2020. In FY2021, the company recorded a net margin of 12.3%, compared to a net margin of 9.4% in FY2020. The company reported revenues of US$65.3 million for the third quarter ended September 2022, an increase of 1.4% over the previous quarter.
Quick View – Tradipitant
|Highest Development Stage|